Payment overview · 2025
General Payments
$58,790.21
92 reported records · 30 companies
Healthcare provider profile · identity verified
Hans Lee, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · NASHVILLE, TN · NPI 1144470758
Verified facts
What the public records show
CMS Open Payments records show Hans Lee, M.D. received $58,790.21 in general payments during 2025 across 92 reported records.
E.R. Squibb & Sons, L.L.C. accounted for 31.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 36 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VENCLEXTA as an associated drug or biological on 10417 records involving 4944 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Venclexta by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported POMALYST as an associated drug or biological on 282 records involving 237 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Pomalyst by this doctor in 2024.
Genentech USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Venclexta as an associated drug or biological on 2896 records involving 2018 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Venclexta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $18,591.30 | 31.6% | 6 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $9,609.50 | 16.4% | 4 | 2025 |
| Menarini Silicon Biosystems, Inc. | Unresolved — no canonical attribution shown | $6,800.00 | 11.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $6,134.82 | 10.4% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $5,746.70 | 9.8% | 8 | 2025 |
| Janssen Scientific Affairs, LLC | Unresolved — no canonical attribution shown | $5,268.81 | 9.0% | 5 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $3,013.16 | 5.1% | 8 | 2025 |
| Janssen Global Services, LLC | Unresolved — no canonical attribution shown | $1,870.81 | 3.2% | 4 | 2025 |
| Legend Biotech USA Inc. | Unresolved — no canonical attribution shown | $308.20 | 0.5% | 5 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $283.53 | 0.5% | 7 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $245.33 | 0.4% | 6 | 2025 |
| MENARINI SILICON BIOSYSTEMS, INC. | Unresolved — no canonical attribution shown | $241.75 | 0.4% | 1 | 2025 |
| Adaptive Biotechnologies Corporation | Unresolved — no canonical attribution shown | $139.44 | 0.2% | 1 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $76.41 | 0.1% | 3 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $53.49 | 0.1% | 3 | 2025 |
| BeOne Medicines USA, Inc. | Unresolved — no canonical attribution shown | $45.60 | 0.1% | 2 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $40.15 | 0.1% | 2 | 2025 |
| Novocure Inc. | Unresolved — no canonical attribution shown | $35.05 | 0.1% | 2 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $34.01 | 0.1% | 2 | 2025 |
| Caris MPI, Inc. | Unresolved — no canonical attribution shown | $30.86 | 0.1% | 2 | 2025 |
| Genmab U.S., Inc. | Unresolved — no canonical attribution shown | $25.28 | 0.0% | 1 | 2025 |
| AVYXA PHARMA, LLC | Unresolved — no canonical attribution shown | $25.13 | 0.0% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $24.35 | 0.0% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $24.12 | 0.0% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $23.76 | 0.0% | 1 | 2025 |
| Ipsen Biopharmaceuticals, Inc | Unresolved — no canonical attribution shown | $20.81 | 0.0% | 1 | 2025 |
| Exelixis Inc. | Unresolved — no canonical attribution shown | $20.58 | 0.0% | 1 | 2025 |
| Invivyd Inc | Unresolved — no canonical attribution shown | $20.20 | 0.0% | 1 | 2025 |
| Celltrion USA Inc. | Unresolved — no canonical attribution shown | $19.57 | 0.0% | 1 | 2025 |
| Tempus AI, Inc | Unresolved — no canonical attribution shown | $17.49 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $44,431.25 | 14 |
| Honoraria | $6,800.00 | 1 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3,339.50 | 2 |
| Food and Beverage | $2,791.75 | 69 |
| Travel and Lodging | $1,427.71 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ELREXFIO Normalized: elrexfio |
Drug | PFIZER INC. | $7,659.50 | 3 | 2025 |
Source payment records
|
|||||
| Cellsearch Normalized: cellsearch |
Device | MENARINI SILICON BIOSYSTEMS, INC., Menarini Silicon Biosystems, Inc. | $7,041.75 | 2 | 2025 |
Source payment records
|
|||||
| BLENREP Normalized: blenrep |
Biological | GlaxoSmithKline, LLC. | $5,896.54 | 5 | 2025 |
Source payment records
|
|||||
| TALVEY Normalized: talvey |
Biological | Janssen Biotech, Inc., Janssen Global Services, LLC, Janssen Scientific Affairs, LLC | $5,263.32 | 10 | 2025 |
Source payment records
|
|||||
| CARVYKTI Normalized: carvykti |
Biological, Drug | Janssen Biotech, Inc., Janssen Global Services, LLC, Legend Biotech USA Inc. | $4,990.21 | 13 | 2025 |
Source payment records
|
|||||
| DARZALEX Normalized: darzalex |
Biological | Janssen Biotech, Inc., Janssen Global Services, LLC | $4,825.21 | 9 | 2025 |
Source payment records
|
|||||
| TECVAYLI Normalized: tecvayli |
Biological | Janssen Biotech, Inc., Janssen Global Services, LLC, Janssen Scientific Affairs, LLC | $2,211.13 | 7 | 2025 |
Source payment records
|
|||||
| LYNOZYFIC Normalized: lynozyfic |
Biological | Regeneron Healthcare Solutions, Inc. | $198.18 | 1 | 2025 |
Source payment records
|
|||||
| clonoSEQ Normalized: clonoseq |
Device | Adaptive Biotechnologies Corporation | $139.44 | 1 | 2025 |
Source payment records
|
|||||
| LIBTAYO Normalized: libtayo |
Biological | Regeneron Healthcare Solutions, Inc. | $85.35 | 6 | 2025 |
Source payment records
|
|||||
| OPDUALAG Normalized: opdualag |
Drug | E.R. Squibb & Sons, L.L.C. | $48.97 | 2 | 2025 |
Source payment records
|
|||||
| Enhertu Normalized: enhertu |
Drug | Daiichi Sankyo Inc. | $48.36 | 2 | 2025 |
Source payment records
|
|||||
| TEVIMBRA Normalized: tevimbra |
Drug | BeOne Medicines USA, Inc. | $45.60 | 2 | 2025 |
Source payment records
|
|||||
| RYBREVANT Normalized: rybrevant |
Drug | Janssen Biotech, Inc. | $38.95 | 2 | 2025 |
Source payment records
|
|||||
| BREYANZI Normalized: breyanzi |
Biological | Celgene Corporation | $37.51 | 2 | 2025 |
Source payment records
|
|||||
| Optune Lua (NovoTTF-200T) Normalized: optune lua novottf 200t |
Device | Novocure Inc. | $35.05 | 2 | 2025 |
Source payment records
|
|||||
| MI CANCER SEEK Normalized: mi cancer seek |
Device | Caris MPI, Inc. | $30.86 | 2 | 2025 |
Source payment records
|
|||||
| DATROWAY Normalized: datroway |
Drug | Daiichi Sankyo Inc. | $28.05 | 1 | 2025 |
Source payment records
|
|||||
| Epkinly Normalized: epkinly |
Drug | Genmab U.S., Inc. | $25.28 | 1 | 2025 |
Source payment records
|
|||||
| DOCIVYX Normalized: docivyx |
Drug | AVYXA PHARMA, LLC | $25.13 | 1 | 2025 |
Source payment records
|
|||||
| FRINDOVYX Normalized: frindovyx |
Drug | AVYXA PHARMA, LLC | $25.13 | 1 | 2025 |
Source payment records
|
|||||
| LUTRATE DEPOT Normalized: lutrate depot |
Drug | AVYXA PHARMA, LLC | $25.13 | 1 | 2025 |
Source payment records
|
|||||
| Lenvima Normalized: lenvima |
Drug | Eisai Inc. | $24.35 | 1 | 2025 |
Source payment records
|
|||||
| KEYTRUDA Normalized: keytruda |
Biological | Merck Sharp & Dohme LLC | $24.12 | 1 | 2025 |
Source payment records
|
|||||
| LYNPARZA Normalized: lynparza |
Biological | Merck Sharp & Dohme LLC | $24.12 | 1 | 2025 |
Source payment records
|
|||||
| Onivyde Normalized: onivyde |
Drug | Ipsen Biopharmaceuticals, Inc | $20.81 | 1 | 2025 |
Source payment records
|
|||||
| CABOMETYX Normalized: cabometyx |
Drug | Exelixis Inc. | $20.58 | 1 | 2025 |
Source payment records
|
|||||
| PEMGARDA Normalized: pemgarda |
Biological | Invivyd Inc | $20.20 | 1 | 2025 |
Source payment records
|
|||||
| BALVERSA Normalized: balversa |
Drug | Janssen Biotech, Inc. | $19.81 | 1 | 2025 |
Source payment records
|
|||||
| ERLEADA Normalized: erleada |
Drug | Janssen Biotech, Inc. | $19.81 | 1 | 2025 |
Source payment records
|
|||||
| Lunsumio Normalized: lunsumio |
Biological | Genentech USA, Inc. | $19.69 | 1 | 2025 |
Source payment records
|
|||||
| VEGZELMA Normalized: vegzelma |
Biological | Celltrion USA Inc. | $19.57 | 1 | 2025 |
Source payment records
|
|||||
| OJJAARA Normalized: ojjaara |
Drug | GlaxoSmithKline, LLC. | $19.55 | 1 | 2025 |
Source payment records
|
|||||
| XT CDX Normalized: xt cdx |
Device | Tempus AI, Inc | $17.49 | 1 | 2025 |
Source payment records
|
|||||
| ABECMA Normalized: abecma |
Biological | Celgene Corporation | $15.98 | 1 | 2025 |
Source payment records
|
|||||
| Tecentriq Normalized: tecentriq |
Biological | Genentech USA, Inc. | $14.32 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VENCLEXTA open payments reported associated product |
CMS Open Payments — General Payments 10417 supporting records · 4944 recipient NPIs · example record 1201353144 |
Venclexta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | POMALYST open payments reported associated product |
CMS Open Payments — General Payments 282 supporting records · 237 recipient NPIs · example record 1184378437 |
Pomalyst · 2024 Exact normalized brand match · 1 Part D row |
87 | 21 |
| Genentech USA, Inc. Exact reporting entity; no affiliate inference |
2025 | Venclexta open payments reported associated product |
CMS Open Payments — General Payments 2896 supporting records · 2018 recipient NPIs · example record 1211488584 |
Venclexta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Revlimid | Lenalidomide | 161 | 31 |
| Lenalidomide | Lenalidomide | 136 | 24 |
| Pomalyst | Pomalidomide | 87 | 21 |
| Valacyclovir | Valacyclovir Hcl | 77 | 39 |
| Dexamethasone | Dexamethasone | 36 | 15 |
| Pantoprazole Sodium | Pantoprazole Sodium | 33 | 23 |
| Ondansetron Hcl | Ondansetron Hcl | 27 | 22 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 18 | suppressed |
| Venclexta | Venetoclax | 12 | suppressed |
| Levofloxacin | Levofloxacin | 11 | 11 |
| Ninlaro | Ixazomib Citrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $58,790.21 · 92 records | E.R. Squibb & Sons, L.L.C. | ABECMA, BALVERSA, BLENREP, BREYANZI, CABOMETYX, CARVYKTI, Cellsearch, DARZALEX, DATROWAY, DOCIVYX, ELREXFIO, ERLEADA, Enhertu, Epkinly, FRINDOVYX, KEYTRUDA, LIBTAYO, LUTRATE DEPOT, LYNOZYFIC, LYNPARZA, Lenvima, Lunsumio, MI CANCER SEEK, OJJAARA, OPDUALAG, Onivyde, Optune Lua (NovoTTF-200T), PEMGARDA, RYBREVANT, TALVEY, TECVAYLI, TEVIMBRA, Tecentriq, VEGZELMA, XT CDX, clonoSEQ | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error